Log in

NASDAQ:PRTOProteon Therapeutics Stock Price, Forecast & News

$26.67
+1.08 (+4.22 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$26.07
Now: $26.67
$27.50
50-Day Range
$24.05
MA: $37.13
$60.70
52-Week Range
$0.22
Now: $26.67
$3.94
Volume6,500 shs
Average Volume1.11 million shs
Market Capitalization$591.51 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Read More
Proteon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTO
CUSIPN/A
Phone781-890-0102

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share

Profitability

Net Income$-20,730,000.00

Miscellaneous

Employees17
Market Cap$591.51 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive PRTO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter.

Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions

How has Proteon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Proteon Therapeutics' stock was trading at $24.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTO stock has increased by 10.2% and is now trading at $26.67. View which stocks have been most impacted by Coronavirus.

When is Proteon Therapeutics' next earnings date?

Proteon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteon Therapeutics.

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.01. View Proteon Therapeutics' earnings history.

Has Proteon Therapeutics been receiving favorable news coverage?

News stories about PRTO stock have been trending positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteon Therapeutics earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news about Proteon Therapeutics.

Who are some of Proteon Therapeutics' key competitors?

What other stocks do shareholders of Proteon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include Celgene (CELG), SCYNEXIS (SCYX), Sierra Oncology (SRRA), Agile Therapeutics (AGRX), Biocept (BIOC), ImmunoGen (IMGN), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP) and TherapeuticsMD (TXMD).

Who are Proteon Therapeutics' key executives?

Proteon Therapeutics' management team includes the following people:
  • Mr. Timothy P. Noyes, Pres, CEO & Director (Age 57)
  • Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 56)
  • Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 58)
  • Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 46)
  • Mr. Bradley J. Hartman, VP of People (Age 38)

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How do I buy shares of Proteon Therapeutics?

Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteon Therapeutics' stock price today?

One share of PRTO stock can currently be purchased for approximately $26.67.

How big of a company is Proteon Therapeutics?

Proteon Therapeutics has a market capitalization of $591.51 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe.

What is Proteon Therapeutics' official website?

The official website for Proteon Therapeutics is www.proteontherapeutics.com.

How can I contact Proteon Therapeutics?

Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.